In addition, it significantly reduced pulmonary fibrosis in the nintedanib+anti-PD-L1 group, whereas evident pulmonary consolidation was observed in the control and anti-PD-L1 groups (45). This evidence concerns the gene CD274 and pulmonary fibrosis.